VistaGen Therapeutics Inc. announced that the PALISADE-3 Phase 3 clinical trial evaluating intranasal fasedienol for the acute treatment of social anxiety disorder did not achieve its primary endpoint. The study found no treatment difference between fasedienol and placebo as measured by the least squares mean change from baseline on the Subjective Units of Distress Scale, nor for the secondary endpoints. The safety profile of fasedienol in the trial was consistent with previous clinical studies. The results have already been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VistaGen Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-25-058594), on December 22, 2025, and is solely responsible for the information contained therein.